medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-13-155-158medsovet-2621Research ArticleПРЕ- И ПОСТМЕНОПАУЗАPRE- AND POSTMENOPAUSEТерапия урогенитальных расстройств в постменопаузеTherapy for urogenital disorders in postmenopausal womenОвсянниковаТ. В.OvsyannikovaT. V.

профессор кафедры акушерства, гинекологии и репродуктивной медицины

КуликовИ. А.KulikovI. A.

доцент кафедры акушерства, гинекологии, перинатологии и репродуктологии

Российский университет дружбы народовРоссияRussian Peoples’ Friendship UniversityRussian FederationИПО Первого МГМУ им. И.М. СеченоваРоссияSechenov First Moscow State Medical UniversityRussian Federation201825092018013155158Copyright © Овсянникова Т.В., Куликов И.А., 20182018Овсянникова Т.В., Куликов И.А.Ovsyannikova T.V., Kulikov I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2621

Представлены данные об этапах старения репродуктивной системы женщины и симптомах, развивающихся в эти возрастные периоды. Отмечено, что в основе патогенеза развития урогенитальных расстройств лежит снижение уровня эстрогенов в пери- и постменопаузе. Эффективной терапией женщин с вагинальной атрофией является назначение препаратов эстриола (Овестин) в виде крема или вагинальных суппозиториев.

Data are presented on the stages of aging of the female reproductive system and the symptoms developing in these age periods. It is noted that the pathogenesis of development of urogenital disorders are connected with decrease in the level of estrogens in the peri- and postmenorausal period. Effective therapy for women with vaginal atrophy is the administration of estriol preparations (Оvestin) in the form of a cream or vaginal suppositories.

климактерийменопаузаурогенитальные расстройстваФСГэстрадиолантимюллеров гормонвагинальная атрофияОвестинсхемы терапииclimactericmenopauseurogenital disordersFSHestradiol anti-mullerian hormonevaginal atrophyOvestintherapy regimensReferencesМенопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Москва, 2014.Menopausal hormone therapy and health preservation of middle-aged women. Moscow, 2014.Harlow SD, Gass M, Hall JD et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric, 2010, 15: 105-114.Harlow SD, Gass M, Hall JD et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric, 2010, 15: 105-114.Avis N.E., Crawford S.L., Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern MED, 2015, 175: 513-539.Avis N.E., Crawford S.L., Greendale G. et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern MED, 2015, 175: 513-539.Randolf J, Zheng H, Sower MR, Change in FSH and estradiol across the menopausal transition: effect of age at final menstrual period. J Clin Endocrinol Metab, 2011, 96: 746-754.Randolf J, Zheng H, Sower MR, Change in FSH and estradiol across the menopausal transition: effect of age at final menstrual period. J Clin Endocrinol Metab, 2011, 96: 746-754.http://www.statdata.ru/spg_reg_rf.http://www.statdata.ru/spg_reg_rf.Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016. 19 (2): 109-150. doi.org/10.3109/13697137.2015.1129166.Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric, 2016. 19 (2): 109-150. doi.org/10.3109/13697137.2015.1129166.The 2017 hormone therapy position statement of The North American Menopause Society Menopause. The Journal of The North American Menopause Society, 2017, 24(7): 728-753. doi. org/10.1097/GME.0000000000000921. 8.The 2017 hormone therapy position statement of The North American Menopause Society Menopause. The Journal of The North American Menopause Society, 2017, 24(7): 728-753. doi. org/10.1097/GME.0000000000000921. 8.Robinson D, Ioozs-Hobson P, Cardoso L. The effect of hormones on the lower urinary tract. Menopause, 2013.19.155-162.Robinson D, Ioozs-Hobson P, Cardoso L. The effect of hormones on the lower urinary tract. Menopause, 2013.19.155-162.Гинекология. Национальное руководство (под ред. Савельевой Г.М., Сухих Г.Т., Серов В.Н. и др.). М.: ГЭОТАР-Медиа. 2017: 275-284. / Gynecology. National guidelines (under the editorship of Savelyeva GM, Sukhikh GT, Serov VN, et al). Moscow: GEOTAR-Media. 2017: 275-284.Gynecology. National guidelines (under the editorship of Savelyeva GM, Sukhikh GT, Serov VN, et al). Moscow: GEOTAR-Media. 2017: 275-284.Овсянникова Т.В., Макаров И.О. и др. Местная терапия урогенитальных нарушений в пери- и постменопаузе. Акушерство, гинекология и репродукция, 2010, 4(3): 25-28.Ovsyannikova TV, Makarov IO, et al. Local therapy of urogenital disorders in peri- and postmenopausal women. Akusherstvo, Ginekologiya i Reproduktsiya, 2010, 4 (3): 25-28.Балан В.Е., Ковалева Л.А., Тихомирова Е.В. Генитоуренальный или урогенитальный синдром. Возможности длительной терапии. Медицинский совет, 2016, 12: 98-101.Balan VE, Kovaleva LA, Tikhomirova EV. Genitourenal or urogenital syndrome. Possibilities of long-term therapy. Meditsinsky Sovet, 2016, 12: 98-101.Rahn D, Ward RV, Sanses TV et al. Sosiety of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disordes. Urogynecol, J, 2015, 26: 3-13.Rahn D, Ward RV, Sanses TV et al. Sosiety of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disordes. Urogynecol, J, 2015, 26: 3-13.Rees M, Perez-Lopez FR, Ceasul I et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal atrophy. Maturitas, 2012, 73: 171-174.Rees M, Perez-Lopez FR, Ceasul I et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal atrophy. Maturitas, 2012, 73: 171-174.Beber RJ, Panay N, Fenton A. IMS Recommendations, Climacteris, 2016.Beber RJ, Panay N, Fenton A. IMS Recommendations, Climacteris, 2016.

The authors declare that there are no conflicts of interest present.